Heart warning for those stopping weight-loss jabs
Heart warning for those stopping weight-loss jabs

People taking weight-loss injections face around twice the risk of a non-fatal heart attack, non-fatal stroke or death from any cause if they stop treatment, according to new research. The findings, based on records from more than 80,000 people with type 2 diabetes, raise fresh questions about what happens when patients discontinue GLP-1 medicines.

Study of over 80,000 patients

Researchers examined the medical records of more than 80,000 people with type 2 diabetes across 301 diabetes clinics in Italy, all of whom had no established cardiovascular disease when the study began. The research, published in The Lancet Regional Health - Europe in November 2026, analysed patient records spanning 2004 to 2024.

The study compared people who stopped taking GLP-1 medication with those who continued treatment. Those who continued used the drugs for nearly three years on average, compared with just over a year among those who stopped.

Risk doubled after stopping

Researchers found that the combined rate of non-fatal heart attack, non-fatal stroke or death from any cause was around twice as high among those who discontinued treatment. The association appeared stronger among people who remained obese after stopping treatment.

Researchers also found that the increased risk was not fully explained by changes in weight, blood sugar or blood pressure. However, the study did not establish why people stopped taking the medication, which was an important limitation when interpreting the findings.

Expert caution on interpretation

Dr Francesco Lo Monaco, cardiologist and founder of the National Longevity Clinic, said the findings highlight the importance of understanding the potential cardiovascular implications of stopping treatment. He said: "GLP-1 medicines are increasingly being used to manage type 2 diabetes and obesity, and we know that these conditions are closely linked to cardiovascular health.

"These findings are interesting because they suggest that the potential benefits of treatment may extend beyond weight loss and blood sugar control. But we need to be very careful about interpreting them."

Dr Lo Monaco added: "This was an observational study. It cannot prove that stopping the medication caused the higher risk. People may have stopped treatment because they were already becoming unwell, or for other reasons that also affected their health."

Should patients stay on jabs indefinitely?

It is estimated that more than 1.5 million people across the UK are taking some form of weight loss injection. However, the study does not mean that everyone taking a GLP-1 medicine must remain on it for life.

There may be valid clinical reasons to stop or change treatment, including side effects, changes in a person's health or a decision made with their healthcare professional. Dr Lo Monaco said: "People should not stop prescribed medication or make changes to their treatment without speaking to their treating clinician first. The right approach will depend on the individual - their medical history, their risk factors and why they are taking the medication in the first place.

"What this research highlights is the importance of having a plan for treatment, including what happens if a patient needs to stop. It is not evidence that everyone needs to remain on these drugs indefinitely."

The researchers said further studies are needed to understand whether stopping GLP-1 treatment directly affects cardiovascular risk, or whether the association reflects differences in the health of people who discontinue treatment.